Healios K.K. (HLOSF)
USD 1.35
(0.0%)
USD 1.35
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.82 Billion JPY | -9600.96% |
| 2022 | -39.4 Million JPY | 7.6% |
| 2021 | -42.64 Million JPY | 20.12% |
| 2020 | -53.38 Million JPY | -20.72% |
| 2019 | -44.22 Million JPY | 99.13% |
| 2018 | -5.09 Billion JPY | -186.89% |
| 2017 | -1.77 Billion JPY | 48.26% |
| 2016 | -3.43 Billion JPY | -43010.12% |
| 2015 | -7.96 Million JPY | 98.33% |
| 2014 | -477.25 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -534 Million JPY | 77.98% |
| 2024 Q1 | -16.02 Million JPY | -40.09% |
| 2023 Q2 | -4.57 Million USD | 16.9% |
| 2023 FY | -3.82 Billion JPY | -9600.96% |
| 2023 Q4 | -12.26 Million USD | -161.51% |
| 2023 Q1 | -5.5 Million USD | 40.5% |
| 2023 Q3 | -4.69 Million USD | -2.59% |
| 2022 Q2 | -13.25 Million JPY | 99.09% |
| 2022 Q4 | -9.24 Million JPY | -92.37% |
| 2022 Q3 | -4.8 Million JPY | 63.73% |
| 2022 Q1 | -1.46 Billion JPY | -20.15% |
| 2022 FY | -39.4 Million JPY | 7.6% |
| 2021 FY | -42.64 Million JPY | 20.12% |
| 2021 Q2 | -7.77 Million JPY | 16.5% |
| 2021 Q4 | -1.21 Billion JPY | 32.56% |
| 2021 Q1 | -9.31 Million JPY | 99.38% |
| 2021 Q3 | -1.8 Billion JPY | -23088.29% |
| 2020 Q1 | -1.26 Billion JPY | 0.16% |
| 2020 FY | -53.38 Million JPY | -20.72% |
| 2020 Q3 | -1.4 Billion JPY | -4.46% |
| 2020 Q2 | -1.34 Billion JPY | -6.49% |
| 2020 Q4 | -1.49 Billion JPY | -6.62% |
| 2019 Q4 | -1.26 Billion JPY | -24.75% |
| 2019 Q3 | -1.01 Billion JPY | 1.93% |
| 2019 Q1 | -937 Million JPY | 9.82% |
| 2019 Q2 | -1.03 Billion JPY | -10.35% |
| 2019 FY | -44.22 Million JPY | 99.13% |
| 2018 Q1 | -553 Million JPY | 2.52% |
| 2018 Q3 | -735 Million JPY | 73.47% |
| 2018 Q2 | -2.77 Billion JPY | -400.9% |
| 2018 FY | -5.09 Billion JPY | -186.89% |
| 2018 Q4 | -1.03 Billion JPY | -41.36% |
| 2017 Q1 | -526 Million JPY | -59.38% |
| 2017 FY | -1.77 Billion JPY | 48.26% |
| 2017 Q2 | 183.7 Million JPY | 134.92% |
| 2017 Q4 | -567.27 Million JPY | 34.54% |
| 2017 Q3 | -866.65 Million JPY | -571.77% |
| 2016 Q2 | -518.35 Million JPY | 75.68% |
| 2016 FY | -3.43 Billion JPY | -43010.12% |
| 2016 Q4 | -330.03 Million JPY | 27.22% |
| 2016 Q3 | -453.49 Million JPY | 12.51% |
| 2016 Q1 | -2.13 Billion JPY | -466.82% |
| 2015 Q2 | -175.93 Million JPY | 27.23% |
| 2015 Q4 | -376.07 Million JPY | -128.88% |
| 2015 Q3 | -164.3 Million JPY | 6.61% |
| 2015 Q1 | -241.78 Million JPY | 0.0% |
| 2015 FY | -7.96 Million JPY | 98.33% |
| 2014 FY | -477.25 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -4999.849% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -58034.663% |
| SQZ Biotechnologies Company | -79.46 Million USD | -4710.984% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 7316.067% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 5969.535% |
| Mesoblast Limited | -87.95 Million USD | -4246.491% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -209894.024% |
| Genus plc | 7.9 Million USD | 48492.405% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -34999.99% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -102939.323% |
| Marizyme, Inc. | -65.34 Million USD | -5750.314% |
| ContraFect Corporation | -65.15 Million USD | -5767.727% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -43127.047% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -78142.953% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -221208.225% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -132074.247% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -47333.633% |
| MultiCell Technologies, Inc. | -380.07 USD | -1005867240.227% |
| Accustem Sciences Inc. | -3.74 Million USD | -101944.112% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -7295.729% |
| EV Biologics, Inc. | -1.26 Million USD | -301604.476% |
| Q BioMed Inc. | -2.05 Million USD | -186197.6% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -102310.93% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -604415.763% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -160471.556% |
| Biomind Labs Inc. | -1.21 Million USD | -314726.664% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -36143.838% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -48273.466% |
| Skye Bioscience, Inc. | -37.64 Million USD | -10055.457% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -176090.217% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -25527410.684% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -54648.529% |
| IMV Inc. | -36.48 Million USD | -10378.079% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -23987.287% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -65618.304% |
| GB Sciences, Inc. | -1.36 Million USD | -280656.743% |
| Alpha Cognition Inc. | -13.77 Million USD | -27658.079% |
| HST Global, Inc. | -146.21 Thousand USD | -2614632.234% |
| CSL Limited | 2.64 Billion USD | 244.701% |
| Halberd Corporation | -79.67 Thousand USD | -4798082.64% |
| Enzolytics Inc. | -2.17 Million USD | -175522.189% |
| Resverlogix Corp. | -3.61 Million USD | -105800.277% |
| Affymax, Inc. | -14.42 Million USD | -26404.437% |
| SYBLEU INC | -180.3 Thousand USD | -2120207.924% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -120444.763% |
| argenx SE | -295.05 Million USD | -1195.699% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -6007.126% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3901120.408% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -96124.685% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -126232.764% |
| AVAX Technologies, Inc. | -6.41 Million USD | -59507.263% |
| Zenith Capital Corp. | -10.59 Million USD | -35979.653% |
| Genscript Biotech Corporation | -95.47 Million USD | -3904.106% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -16448570.51% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -92110.782% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -6325117.432% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -6300.962% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -123152.287% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -361906.975% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -196026.816% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -100004.739% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -190562.381% |
| BioStem Technologies, Inc. | -8.48 Million USD | -44966.689% |
| ONE Bio Corp. | 8.67 Million USD | 44160.977% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -866068.671% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -286174.618% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -217763.186% |
| Agentix Corp. | -1.37 Million USD | -278095.998% |
| LadRx Corporation | 400.44 Thousand USD | 954792.678% |
| Cell Source, Inc. | -5.32 Million USD | -71744.535% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -920042.775% |
| Regen BioPharma, Inc. | 1.02 Million USD | 373619.308% |
| Regen BioPharma, Inc. | 1.02 Million USD | 373619.308% |
| NovAccess Global Inc. | -4.76 Million USD | -80060.413% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 55309.013% |
| Itoco Inc. | -1.86 Million USD | -204448.434% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -85954.471% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -228959.317% |
| Kadimastem Ltd | -3.3 Million USD | -115489.355% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1398207.255% |
| CytoDyn Inc. | -49.84 Million USD | -7570.392% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -4837119.895% |
| Mobile Lads Corp. | -2.26 Million USD | -168813.247% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1675720.924% |
| Qrons Inc. | -789.34 Thousand USD | -484224.385% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -405941.662% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -183021.759% |
| Rebus Holdings, Inc. | -1.02 Million USD | -374703.922% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -236950.43% |
| International Stem Cell Corporation | -131 Thousand USD | -2918220.611% |
| Bioxytran, Inc. | -4.28 Million USD | -89222.388% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -7044047.995% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -150991.968% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -7852.654% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -180742.006% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -489471.474% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -120575.505% |
| Neutra Corp. | -233.46 Thousand USD | -1637404.551% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -18740.865% |
| PureTech Health plc | -65.69 Million USD | -5719.139% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -17876.599% |
| IXICO plc | -1.17 Million USD | -324433.107% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -38411.131% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -6591.99% |
| CSL Limited | 2.64 Billion USD | 244.701% |
| Cellectis S.A. | -103.17 Million USD | -3605.396% |